Beyond DNA sensing: expanding the role of cGAS/STING in immunity and diseases
Arch Pharm Res. 2023 Jun 24. doi: 10.1007/s12272-023-01452-3. Online ahead of print.ABSTRACTCyclic guanosine monophosphate-adenosine monophosphate (cGAMP) synthase (cGAS) is a DNA sensor that elicits a robust type I interferon response by recognizing ubiquitous danger-associated molecules. The cGAS/stimulator of interferon genes (cGAS/STING) is activated by endogenous DNA, including DNA released from mitochondria and extranuclear chromatin, as well as exogenous DNA derived from pathogenic microorganisms. cGAS/STING is positioned as a key axis of autoimmunity, the inflammatory response, and cancer progression, suggesting th...
Source: Archives of Pharmacal Research - June 24, 2023 Category: Drugs & Pharmacology Authors: Jin Kyung Seok Minhyuk Kim Han Chang Kang Yong-Yeon Cho Hye Suk Lee Joo Young Lee Source Type: research
Beyond DNA sensing: expanding the role of cGAS/STING in immunity and diseases
Arch Pharm Res. 2023 Jun 24. doi: 10.1007/s12272-023-01452-3. Online ahead of print.ABSTRACTCyclic guanosine monophosphate-adenosine monophosphate (cGAMP) synthase (cGAS) is a DNA sensor that elicits a robust type I interferon response by recognizing ubiquitous danger-associated molecules. The cGAS/stimulator of interferon genes (cGAS/STING) is activated by endogenous DNA, including DNA released from mitochondria and extranuclear chromatin, as well as exogenous DNA derived from pathogenic microorganisms. cGAS/STING is positioned as a key axis of autoimmunity, the inflammatory response, and cancer progression, suggesting th...
Source: Archives of Pharmacal Research - June 24, 2023 Category: Drugs & Pharmacology Authors: Jin Kyung Seok Minhyuk Kim Han Chang Kang Yong-Yeon Cho Hye Suk Lee Joo Young Lee Source Type: research
Paritaprevir ameliorates experimental acute lung injury in vitro and in vivo
In this study, we investigated the effect of paritaprevir on a lipopolysaccharide (LPS)-induced two-hit rat ALI model. The anti-ALI mechanism of paritaprevir was also studied in human pulmonary microvascular endothelial (HM) cells following LPS-induced injury in vitro. Administration of 30 mg/kg paritaprevir for 3 days protected rats from LPS-induced ALI, as reflected by the changes in the lung coefficient (from 0.75 to 0.64) and lung pathology scores (from 5.17 to 5.20). Furthermore, the levels of the protective adhesion protein VE-cadherin and tight junction protein claudin-5 increased, and the cytoplasmic p-FOX-O1 and n...
Source: Archives of Pharmacal Research - June 12, 2023 Category: Drugs & Pharmacology Authors: Rui Ren Xin Wang Zehui Xu Wanglin Jiang Source Type: research
Paritaprevir ameliorates experimental acute lung injury in vitro and in vivo
In this study, we investigated the effect of paritaprevir on a lipopolysaccharide (LPS)-induced two-hit rat ALI model. The anti-ALI mechanism of paritaprevir was also studied in human pulmonary microvascular endothelial (HM) cells following LPS-induced injury in vitro. Administration of 30 mg/kg paritaprevir for 3 days protected rats from LPS-induced ALI, as reflected by the changes in the lung coefficient (from 0.75 to 0.64) and lung pathology scores (from 5.17 to 5.20). Furthermore, the levels of the protective adhesion protein VE-cadherin and tight junction protein claudin-5 increased, and the cytoplasmic p-FOX-O1 and n...
Source: Archives of Pharmacal Research - June 12, 2023 Category: Drugs & Pharmacology Authors: Rui Ren Xin Wang Zehui Xu Wanglin Jiang Source Type: research
Paritaprevir ameliorates experimental acute lung injury in vitro and in vivo
In this study, we investigated the effect of paritaprevir on a lipopolysaccharide (LPS)-induced two-hit rat ALI model. The anti-ALI mechanism of paritaprevir was also studied in human pulmonary microvascular endothelial (HM) cells following LPS-induced injury in vitro. Administration of 30 mg/kg paritaprevir for 3 days protected rats from LPS-induced ALI, as reflected by the changes in the lung coefficient (from 0.75 to 0.64) and lung pathology scores (from 5.17 to 5.20). Furthermore, the levels of the protective adhesion protein VE-cadherin and tight junction protein claudin-5 increased, and the cytoplasmic p-FOX-O1 and n...
Source: Archives of Pharmacal Research - June 12, 2023 Category: Drugs & Pharmacology Authors: Rui Ren Xin Wang Zehui Xu Wanglin Jiang Source Type: research
Paritaprevir ameliorates experimental acute lung injury in vitro and in vivo
In this study, we investigated the effect of paritaprevir on a lipopolysaccharide (LPS)-induced two-hit rat ALI model. The anti-ALI mechanism of paritaprevir was also studied in human pulmonary microvascular endothelial (HM) cells following LPS-induced injury in vitro. Administration of 30 mg/kg paritaprevir for 3 days protected rats from LPS-induced ALI, as reflected by the changes in the lung coefficient (from 0.75 to 0.64) and lung pathology scores (from 5.17 to 5.20). Furthermore, the levels of the protective adhesion protein VE-cadherin and tight junction protein claudin-5 increased, and the cytoplasmic p-FOX-O1 and n...
Source: Archives of Pharmacal Research - June 12, 2023 Category: Drugs & Pharmacology Authors: Rui Ren Xin Wang Zehui Xu Wanglin Jiang Source Type: research
Paritaprevir ameliorates experimental acute lung injury in vitro and in vivo
In this study, we investigated the effect of paritaprevir on a lipopolysaccharide (LPS)-induced two-hit rat ALI model. The anti-ALI mechanism of paritaprevir was also studied in human pulmonary microvascular endothelial (HM) cells following LPS-induced injury in vitro. Administration of 30 mg/kg paritaprevir for 3 days protected rats from LPS-induced ALI, as reflected by the changes in the lung coefficient (from 0.75 to 0.64) and lung pathology scores (from 5.17 to 5.20). Furthermore, the levels of the protective adhesion protein VE-cadherin and tight junction protein claudin-5 increased, and the cytoplasmic p-FOX-O1 and n...
Source: Archives of Pharmacal Research - June 12, 2023 Category: Drugs & Pharmacology Authors: Rui Ren Xin Wang Zehui Xu Wanglin Jiang Source Type: research
Paritaprevir ameliorates experimental acute lung injury in vitro and in vivo
In this study, we investigated the effect of paritaprevir on a lipopolysaccharide (LPS)-induced two-hit rat ALI model. The anti-ALI mechanism of paritaprevir was also studied in human pulmonary microvascular endothelial (HM) cells following LPS-induced injury in vitro. Administration of 30 mg/kg paritaprevir for 3 days protected rats from LPS-induced ALI, as reflected by the changes in the lung coefficient (from 0.75 to 0.64) and lung pathology scores (from 5.17 to 5.20). Furthermore, the levels of the protective adhesion protein VE-cadherin and tight junction protein claudin-5 increased, and the cytoplasmic p-FOX-O1 and n...
Source: Archives of Pharmacal Research - June 12, 2023 Category: Drugs & Pharmacology Authors: Rui Ren Xin Wang Zehui Xu Wanglin Jiang Source Type: research
Paritaprevir ameliorates experimental acute lung injury in vitro and in vivo
In this study, we investigated the effect of paritaprevir on a lipopolysaccharide (LPS)-induced two-hit rat ALI model. The anti-ALI mechanism of paritaprevir was also studied in human pulmonary microvascular endothelial (HM) cells following LPS-induced injury in vitro. Administration of 30 mg/kg paritaprevir for 3 days protected rats from LPS-induced ALI, as reflected by the changes in the lung coefficient (from 0.75 to 0.64) and lung pathology scores (from 5.17 to 5.20). Furthermore, the levels of the protective adhesion protein VE-cadherin and tight junction protein claudin-5 increased, and the cytoplasmic p-FOX-O1 and n...
Source: Archives of Pharmacal Research - June 12, 2023 Category: Drugs & Pharmacology Authors: Rui Ren Xin Wang Zehui Xu Wanglin Jiang Source Type: research
Paritaprevir ameliorates experimental acute lung injury in vitro and in vivo
In this study, we investigated the effect of paritaprevir on a lipopolysaccharide (LPS)-induced two-hit rat ALI model. The anti-ALI mechanism of paritaprevir was also studied in human pulmonary microvascular endothelial (HM) cells following LPS-induced injury in vitro. Administration of 30 mg/kg paritaprevir for 3 days protected rats from LPS-induced ALI, as reflected by the changes in the lung coefficient (from 0.75 to 0.64) and lung pathology scores (from 5.17 to 5.20). Furthermore, the levels of the protective adhesion protein VE-cadherin and tight junction protein claudin-5 increased, and the cytoplasmic p-FOX-O1 and n...
Source: Archives of Pharmacal Research - June 12, 2023 Category: Drugs & Pharmacology Authors: Rui Ren Xin Wang Zehui Xu Wanglin Jiang Source Type: research
Paritaprevir ameliorates experimental acute lung injury in vitro and in vivo
In this study, we investigated the effect of paritaprevir on a lipopolysaccharide (LPS)-induced two-hit rat ALI model. The anti-ALI mechanism of paritaprevir was also studied in human pulmonary microvascular endothelial (HM) cells following LPS-induced injury in vitro. Administration of 30 mg/kg paritaprevir for 3 days protected rats from LPS-induced ALI, as reflected by the changes in the lung coefficient (from 0.75 to 0.64) and lung pathology scores (from 5.17 to 5.20). Furthermore, the levels of the protective adhesion protein VE-cadherin and tight junction protein claudin-5 increased, and the cytoplasmic p-FOX-O1 and n...
Source: Archives of Pharmacal Research - June 12, 2023 Category: Drugs & Pharmacology Authors: Rui Ren Xin Wang Zehui Xu Wanglin Jiang Source Type: research
Paritaprevir ameliorates experimental acute lung injury in vitro and in vivo
In this study, we investigated the effect of paritaprevir on a lipopolysaccharide (LPS)-induced two-hit rat ALI model. The anti-ALI mechanism of paritaprevir was also studied in human pulmonary microvascular endothelial (HM) cells following LPS-induced injury in vitro. Administration of 30 mg/kg paritaprevir for 3 days protected rats from LPS-induced ALI, as reflected by the changes in the lung coefficient (from 0.75 to 0.64) and lung pathology scores (from 5.17 to 5.20). Furthermore, the levels of the protective adhesion protein VE-cadherin and tight junction protein claudin-5 increased, and the cytoplasmic p-FOX-O1 and n...
Source: Archives of Pharmacal Research - June 12, 2023 Category: Drugs & Pharmacology Authors: Rui Ren Xin Wang Zehui Xu Wanglin Jiang Source Type: research
Harnessing deep learning into hidden mutations of neurological disorders for therapeutic challenges
Arch Pharm Res. 2023 Jun 1. doi: 10.1007/s12272-023-01450-5. Online ahead of print.ABSTRACTThe relevant study of transcriptome-wide variations and neurological disorders in the evolved field of genomic data science is on the rise. Deep learning has been highlighted utilizing algorithms on massive amounts of data in a human-like manner, and is expected to predict the dependency or druggability of hidden mutations within the genome. Enormous mutational variants in coding and noncoding transcripts have been discovered along the genome by far, despite of the fine-tuned genetic proofreading machinery. These variants could be ca...
Source: Archives of Pharmacal Research - June 1, 2023 Category: Drugs & Pharmacology Authors: Sumin Yang Sung-Hyun Kim Mingon Kang Jae-Yeol Joo Source Type: research
Harnessing deep learning into hidden mutations of neurological disorders for therapeutic challenges
Arch Pharm Res. 2023 Jun 1. doi: 10.1007/s12272-023-01450-5. Online ahead of print.ABSTRACTThe relevant study of transcriptome-wide variations and neurological disorders in the evolved field of genomic data science is on the rise. Deep learning has been highlighted utilizing algorithms on massive amounts of data in a human-like manner, and is expected to predict the dependency or druggability of hidden mutations within the genome. Enormous mutational variants in coding and noncoding transcripts have been discovered along the genome by far, despite of the fine-tuned genetic proofreading machinery. These variants could be ca...
Source: Archives of Pharmacal Research - June 1, 2023 Category: Drugs & Pharmacology Authors: Sumin Yang Sung-Hyun Kim Mingon Kang Jae-Yeol Joo Source Type: research
Harnessing deep learning into hidden mutations of neurological disorders for therapeutic challenges
Arch Pharm Res. 2023 Jun 1. doi: 10.1007/s12272-023-01450-5. Online ahead of print.ABSTRACTThe relevant study of transcriptome-wide variations and neurological disorders in the evolved field of genomic data science is on the rise. Deep learning has been highlighted utilizing algorithms on massive amounts of data in a human-like manner, and is expected to predict the dependency or druggability of hidden mutations within the genome. Enormous mutational variants in coding and noncoding transcripts have been discovered along the genome by far, despite of the fine-tuned genetic proofreading machinery. These variants could be ca...
Source: Archives of Pharmacal Research - June 1, 2023 Category: Drugs & Pharmacology Authors: Sumin Yang Sung-Hyun Kim Mingon Kang Jae-Yeol Joo Source Type: research
